{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:30:36Z","timestamp":1790890236128,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04653-4","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:01:27Z","timestamp":1744934487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The efficacy and safety of specific therapies for cardiac Transthyretin-mediated amyloidosis: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Alonzo Armani","family":"Prata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Shih","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Gabriel","family":"Scardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Covre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Falco","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Marques","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Scarpioni","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Petri","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanio L. J.","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Gioli-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"1","key":"4653_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, et al. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nuclear Cardiology: Official Publication Am Soc Nuclear Cardiol Vol. 2019;26(1):158\u201373. https:\/\/doi.org\/10.1007\/s12350-018-01552-4.","journal-title":"J Nuclear Cardiology: Official Publication Am Soc Nuclear Cardiol Vol"},{"key":"4653_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, et al. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art review. J Am Coll Cardiol Vol. 2019;73:2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol Vol"},{"issue":"9","key":"4653_CR3","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail Vol. 2022;24(9):1677\u201396. https:\/\/doi.org\/10.1002\/ejhf.2589.","journal-title":"Eur J Heart Fail Vol"},{"issue":"11","key":"4653_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"S Maurer, Mathew","year":"2018","unstructured":"Maurer, Mathew S, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New Engl J Med Vol. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"New Engl J Med Vol"},{"issue":"4","key":"4653_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-Mediated amyloidosis. Circulation Vol. 2019;139(4):431\u201343. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035831.","journal-title":"Circulation Vol"},{"key":"4653_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"S Maurer, Mathew","year":"2023","unstructured":"Maurer, Mathew S, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. New Engl J Med Vol. 2023;389:1553\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2300757.","journal-title":"New Engl J Med Vol"},{"issue":"1","key":"4653_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, et al. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid: Int J Experimental Clin Invest: Official J Int Soc Amyloidosis Vol. 2023;30(1):1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985.","journal-title":"Amyloid: Int J Experimental Clin Invest: Official J Int Soc Amyloidosis Vol"},{"key":"4653_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","author":"M Fontana","year":"2024","unstructured":"Fontana M, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. The new England journal of medicine, 10.1056\/NEJMoa2409134. 30 Aug. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"30 Aug"},{"issue":"1","key":"4653_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New Engl J Med Vol. 2018;379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793.","journal-title":"New Engl J Med Vol"},{"key":"4653_CR10","doi-asserted-by":"publisher","unstructured":"Coelho T et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330,15 (2023): 1448\u201358. https:\/\/doi.org\/10.1001\/jama.2023.18688","DOI":"10.1001\/jama.2023.18688"},{"issue":"2","key":"4653_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. New Engl J Med Vol. 2024;390(2):132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2305434.","journal-title":"New Engl J Med Vol"},{"issue":"3","key":"4653_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol Vol. 2019;74(3):285\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.012.","journal-title":"J Am Coll Cardiol Vol"},{"key":"4653_CR13","doi-asserted-by":"publisher","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 29 Mar. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71. (Clinical research ed.).","DOI":"10.1136\/bmj.n71"},{"key":"4653_CR14","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"4653_CR15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res Vol. 2018;27(6):1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat Methods Med Res Vol"},{"key":"4653_CR16","doi-asserted-by":"publisher","unstructured":"Wan X et al. Dec. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC medical research methodology vol. 14 135. 19 2014, https:\/\/doi.org\/10.1186\/1471-2288-14-135","DOI":"10.1186\/1471-2288-14-135"},{"key":"4653_CR17","unstructured":"https:\/\/training.cochrane.org\/resource\/revman-calculator"},{"key":"4653_CR18","doi-asserted-by":"publisher","unstructured":"Sterne JAC et al. Aug. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.) vol. 366 l4898. 28 2019, https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"4653_CR19","doi-asserted-by":"publisher","unstructured":"Sterne JAC et al. Jul. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clinical research ed.) vol. 343 d4002. 22 2011, https:\/\/doi.org\/10.1136\/bmj.d4002","DOI":"10.1136\/bmj.d4002"},{"key":"4653_CR20","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org\/handbook. When referring to a specific chapter or subsection refer to it by the title and section number, not page numbers."},{"issue":"4","key":"4653_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, et al. How to perform a meta-analysis with R: a practical tutorial. Evidence-based Mental Health Vol. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evidence-based Mental Health Vol"},{"key":"4653_CR22","unstructured":"Trial Sequential Analysis (TSA). [Computer program]. Version 0.9.5.10 beta. the Copenhagen trial unit, centre for clinical intervention research, the capital region. Copenhagen University Hospital\u2013 Rigshospitalet; 2021."},{"key":"4653_CR23","doi-asserted-by":"publisher","unstructured":"Brailovsky Y et al. Mar. TTR Amyloidosis: Current State of Affairs and Promise for the Future. JACC. Case reports vol. 10 101759. 15 2023, https:\/\/doi.org\/10.1016\/j.jaccas.2023.101759","DOI":"10.1016\/j.jaccas.2023.101759"},{"issue":"6","key":"4653_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s11912-023-01397-2","volume":"25","author":"MR Tsoi","year":"2023","unstructured":"Tsoi MR, et al. Emerging therapies for transthyretin amyloidosis. Curr Oncol Rep Vol. 2023;25(6):549\u201358. https:\/\/doi.org\/10.1007\/s11912-023-01397-2.","journal-title":"Curr Oncol Rep Vol"},{"key":"4653_CR25","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P et al. Jun. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS). Journal of cardiac failure, S1071-9164(24)00222-7. 21 2024, https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.003","DOI":"10.1016\/j.cardfail.2024.06.003"},{"key":"4653_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.07.011","author":"OA Smiseth","year":"2024","unstructured":"Smiseth OA, et al. Myocardial Strain Imaging: Theory, Current Practice, and the Future. JACC. Cardiovascular imaging, S1936-878X(24)00301-2. 26 Aug. 2024. https:\/\/doi.org\/10.1016\/j.jcmg.2024.07.011.","journal-title":"26 Aug"},{"key":"4653_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","volume":"14","author":"R Huntjens, Peter","year":"2021","unstructured":"Huntjens, Peter R, et al. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC. Cardiovasc Imaging Vol. 2021;14:1508\u201319. https:\/\/doi.org\/10.1016\/j.jcmg.2021.01.016.","journal-title":"Cardiovasc Imaging Vol"},{"key":"4653_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko L, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J Vol. 2020;41:1439\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehz905.","journal-title":"Eur Heart J Vol"},{"key":"4653_CR29","doi-asserted-by":"publisher","unstructured":"Nakano T et al. May. Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function. Journal of personalized medicine vol. 12,5 792. 13 2022, https:\/\/doi.org\/10.3390\/jpm12050792","DOI":"10.3390\/jpm12050792"},{"key":"4653_CR30","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/ehf2.14815","volume":"11","author":"S Dobner","year":"2024","unstructured":"Dobner S, et al. Impact of Tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy. ESC Heart Fail Vol. 2024;11:2759\u201368. https:\/\/doi.org\/10.1002\/ehf2.14815.","journal-title":"ESC Heart Fail Vol"},{"issue":"1","key":"4653_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","volume":"84","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, et al. Prognostic value of a 6-Minute walk test in patients with transthyretin cardiac amyloidosis. J Am Coll Cardiol Vol. 2024;84(1):43\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.011.","journal-title":"J Am Coll Cardiol Vol"},{"key":"4653_CR32","doi-asserted-by":"publisher","unstructured":"Judge DP et al. Nov. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2024;18. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072771.","DOI":"10.1161\/CIRCULATIONAHA.124.072771"},{"key":"4653_CR33","doi-asserted-by":"publisher","unstructured":"Elliott P et al. Long-Term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 15,1 (2022): e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193"},{"key":"4653_CR34","doi-asserted-by":"publisher","unstructured":"Hellenbart EL et al. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications. Pharmacotherapy 45,2 (2025): 124\u201344. https:\/\/doi.org\/10.1002\/phar.4639","DOI":"10.1002\/phar.4639"},{"key":"4653_CR35","unstructured":"Wasfy JH, Winn AN, Touchette DR et al. Disease Modifying Therapies for the Treatment of Transthyretin Amyloid Cardiomyopathy. 2024. Draft Evidence Report. Institute for Clinical and Economic Review. https:\/\/icer.org\/assessment\/transthyretin-amyloid\u2010cardiomyopathy\u20102024"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04653-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:23:19Z","timestamp":1758871399000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04653-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4653"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04653-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants, animal subjects, or any data requiring ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}